相关实验视频

Updated: May 12, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

对于具有常见EGFR激活突变的高级非小细胞肺癌的治疗正在发展

Igor Gomez-Randulfe¹, Federico Monaca², David Planchard³

¹Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

Critical reviews in oncology/hematology

|May 5, 2025

概括

新的策略正在改善EGFR突变非小细胞肺癌 (NSCLC) 的结果. 结合治疗和向抗药机制,为患有这种常见癌症亚型的患者延长生存期提供了希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

皮表皮生长因子受体 (EGFR) 突变驱动非小细胞肺癌 (NSCLC) 的重要子集.
EGFR氨酸激酶抑制剂 (TKIs) 的治疗方法已经很先进,但获得的耐药性仍然是一个挑战.
第三代TKI如奥西默提尼布显示出改善的结果,但生存率的增加是有限的.

研究的目的:

审查EGFR突变NSCLC的当前和新兴治疗策略.
讨论克服对EGFR TKIs的耐药性的方法.
为突出未来的NSCLC个性化治疗方向.

主要方法:

临床试验数据和EGFR突变NSCLC治疗的新兴研究的审查.
对组合疗法的分析,包括抗血管原药,化疗和双特异性抗体.
探索针对MET放大和抗体-药物合物等耐药机制的新型药物.

主要成果:

第一代,第二代和第三代EGFRTKIs改善了结果,第三代TKIs显示出更高的无进展和整体存活率.
前期强化策略和新的组合显示出扩大疾病控制的前景.
目前正在研究针对抗药机制的新兴疗法和以生物标志物为导向的方法.

结论:

尽管取得了进展,但EGFR突变性NSCLC的总生存时间中位数仍然在3年左右.
针对抗药机制的组合疗法和新药对于进一步改善生存至关重要.
个性化,生物标志物驱动的治疗顺序对于优化EGFR突变NSCLC患者的结果至关重要.

关键词:

在前面和后面的朋友.抗体与药物的结合物.欧洲农业基金会 (EGFR) 是一个基金.非小细胞肺癌是非小细胞肺癌.奥西默蒂尼布 (Osimertinib) 是一种药物.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.